Company news

Puma Biotechnology Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results

October 22, 2026

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026

Puma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 18, 2026

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 17, 2026

Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

September 9, 2026

Puma Biotechnology Reports Inducement Awards under Nasdaq Listing Rule 5635(4)

September 4, 2026

Puma Biotechnology Reports Second Quarter 2026 Financial Results

August 6, 2026

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

July 23, 2026

Puma Biotechnology Reports First Quarter 2026 Financial Results

May 7, 2026

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

April 23, 2026

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2026

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference

February 23, 2026

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

January 7, 2026

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

December 22, 2025

Puma Biotechnology Reports Third Quarter 2025 Financial Results

November 6, 2025

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

October 23, 2025

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635c4

October 3, 2025

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Puma Biotechnology Reports Second Quarter Financial Results

August 7, 2025

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 24, 2025

Puma Biotechnology Reports First Quarter Financial Results

May 8, 2025

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

April 28, 2025

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

April 24, 2025

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

March 26, 2025

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

March 5, 2025

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference

February 26, 2025

Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

December 22, 2024

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

November 19, 2024

Puma Biotechnology Reports Third Quarter 2024 Financial Results

November 6, 2024

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

June 2, 2024

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

June 1, 2024

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 22, 2024

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

March 19, 2024

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

February 12, 2024

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

December 10, 2023

Puma Biotechnology Reports Third Quarter 2023 Financial Results

November 1, 2023

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

October 13, 2023

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

August 7, 2023

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

June 3, 2023

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

March 13, 2023

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

March 1, 2023

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

Puma Biotechnology Releases Updated Corporate Presentation

January 8, 2023

Puma Biotechnology Reports Third Quarter 2022 Financial Results

November 2, 2022

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium

October 26, 2022

Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor

September 19, 2022

Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.